SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-011868
Filing Date
2023-07-13
Accepted
2023-07-13 16:41:59
Documents
13
Period of Report
2023-07-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K plx-20230713x8k.htm   iXBRL 8-K 38113
  Complete submission text file 0001558370-23-011868.txt   247661

Data Files

Seq Description Document Type Size
2 EX-101.SCH plx-20230713.xsd EX-101.SCH 3462
3 EX-101.LAB plx-20230713_lab.xml EX-101.LAB 1351
4 EX-101.PRE plx-20230713_pre.xml EX-101.PRE 11107
7 EXTRACTED XBRL INSTANCE DOCUMENT plx-20230713x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 231087149
SIC: 2836 Biological Products, (No Diagnostic Substances)